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Abstract
Background: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently
in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer
cell resistance to these drugs has not been studied in detail.
Methods: Here, we introduce an analogue of CHS-828 called TP201565 with increased potency in cellular assays.
Further, we describe and characterize a panel of cell lines with acquired stable resistance towards several NAMPT
inhibitors of 18 to 20,000 fold compared to their parental cell lines.
Results: We find that 4 out of 5 of the resistant sublines display mutations of NAMPT located in the vicinity of the
active site or in the dimer interface of NAMPT. Furthermore, we show that these mutations are responsible for the
resistance observed. All the resistant cell lines formed xenograft tumours in vivo. Also, we confirm CHS-828 and
TP201565 as competitive inhibitors of NAMPT through docking studies and by NAMPT precipitation from cellular
lysate by an analogue of TP201565 linked to sepharose. The NAMPT precipitation could be inhibited by addition of
APO866.
Conclusion: We found that CHS-828 and TP201565 are competitive inhibitors of NAMPT and that acquired
resistance towards NAMPT inhibitors can be expected primarily to be caused by mutations in NAMPT.
Background
Drug resistance is a serious concern in the treatment of
cancer [1]. It can occur as either de novo or acquired
resistance following therapy. Besides multi-drug resis-
tance (MDR) caused by ABC efflux pumps, several tar-
geted therapies have described the development of
target-specific drug resistance. Thus, up to 90% of the
cases of acquired resistance to tyrosine kinase inhibitors
are due to over-expression of, or mutations in, the tar-
g e tk i n a s e[ 2 - 4 ] .A c q u i r e dr e s i s t a n c ec a nb es t u d i e db y
inducing resistance in vitro by growing cells in the pre-
sence of increasing concentrations of drug [1].
NAD is an essential cofactor in cell energy production
and metabolism as well as the substrate for mono-
ADP-ribosyltransferases [5], poly-(ADP-ribose) poly-
merases (PARPs) [6] and sirtuins [7], all of these con-
verting NAD to nicotinamide. PARPs are involved in
DNA repair whereas sirtuins can increase cancer cell
survival. To survive under stress and supply metabolites
for cell growth malignant cells depend heavily on aero-
bic glycolysis for generation of ATP [8]. Glycolysis
requires relatively more NAD to generate ATP com-
pared to the oxidative phosphorylation normally occur-
ring in non-malignant tissues. Also, cancer cells may
display increased expression or activity of PARPs [9-11]
and sirtuins [7] for increased DNA repair and cell survi-
val. The first, rate-limiting step in the resynthesis path-
way of NAD from nicotinamide is catalyzed by
nicotinamide phosphoribosyltransferase (NAMPT) [12].
Nicotinamide is converted to nicotinamide mononucleo-
tide (NMN) using 5-phosphoribosyl-1-pyrophosphate
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by NMN adenyltransferase (NMNAT) [13]. The crystal
structure of NAMPT has been resolved and it has been
identified as a dimer belonging to the family of type II
phosphoribosyltransferases [14-16] - each monomer con-
taining two domains. The dimer contains two binding
sites for nicotinamide located in the vicinity of the dimer
interface and residues of both monomers may be part of
the binding site. Inhibition of NAMPT leads to depletion
of NAD [17], secondarily leading to reduction of ATP
and later, cell death. Also, it leads to substrate depletion
of PARPs and sirtuins and furthermore, both PARPs and
sirtuins are inhibited by nicotinamide [18-20]. Tumour
cells are more sensitive to NAMPT inhibition and NAD
depletion due to increased ATP and NAD consumption
[17]. NAMPT inhibition shows high efficacy in haemato-
logical malignancies in preclinical studies [21]. APO866
is a specific, competitive, potent inhibitor of NAMPT
that displays cytotoxicity in a broad panel of cell lines
(Figure 1) [17,22]. APO866 has completed a phase I trial
in oncology [22] and is currently undergoing several
phase II trials for advanced melanoma and cutaneous T-
cell lymphoma as well as a phase I/II trial for refractory
and relapsed B-chronic lymphocytic leukaemia.
CHS-828 (Figure 1), a pyridyl cyanoguanidine, is a small
molecule inhibitor displaying cytotoxicity in a broad panel
of cell lines [23]. We previously identified CHS-828 as an
inhibitor of NAD synthesis [24]. We found CHS-828 to
function similarly to APO866 in a number of assays
although the two compounds are chemically distinct.
Therefore, we suggested CHS-828 as an inhibitor of
NAMPT. Furthermore, we compared a cell line, NYH/
CHS, with acquired, specific resistance towards CHS-828
with its wild type counterpart without identifying the
molecular basis for the resistance observed towards CHS-
828 and APO866. CHS-828 has completed several phase I
trials in oncology [25,26] and a prodrug EB1627/
GMX1777 is currently also in phase I trials [27].
H e r e ,w ep r e s e n tan o v e l ,p o t e n ta n a l o g u eo fC H S -
828, namely TP201565 (Figure 1). This compound was
found as part of a screen for NAMPT inhibitors and has
shown activity in xenograft models. We developed a
number of cell lines resistant to APO866 and TP201565.
In most (4/5) of these we find mutations in the NAMPT
gene that confer resistance when transfected into sensi-
tive cells. The resistant cell lines show tumourigenicity
in xenograft mouse models and in vivo resistance.
Furthermore, through computer modelling and in vitro
biochemistry we find that APO866, CHS-828 and
TP201565 share a binding site in the active site of
NAMPT, thus conclusively identifying CHS-828 and
TP201565 as competitive inhibitors of NAMPT.
Methods
Drugs and chemicals
CHS-828 was synthesized as previously described [28].
APO866 and TP201565 and its linkable analogue were
obtained from TopoTarget A/S (Copenhagen, Den-
mark). All other chemicals used in this paper were
obtained from Sigma (St. Louis, MO, USA).
Cell lines
NYH and NYH/CHS have been described previously
[24]. HCT-116, PC-3 and HEK293T were obtained from
ATCC. To obtain resistance towards NAMPT inhibitors,
the cell lines were cultured in a medium containing the
drug in gradually increasing doses. This process was
continued over an extended period of time until a level
of stable, high-grade resistance was reached.
Clonogenic assay
Cells were incubated with the drug at different concen-
trations, in triplicates with a 3-week incubation period.
Afterwards, the colonies were counted as described pre-
viously [29]. The colonies were counted in triplicate.
Western blotting
Western blotting of NAMPT and GAPDH was performed
as described before [24]. The anti-rabbit PBEF antibody
(Bethyl Laboratories, Montgomery, TX, USA) was used for
Figure 1 Chemical structures of APO866, CHS-828 and
TP201565. APO866 and CHS-828 are chemically distinct whereas
TP201565 is an analogue of CHS-828.
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metry measurements were done using Quantity One soft-
ware (Bio-Rad Laboratories, Hercules, CA, USA) and
results were averaged from 2-3 separate blots.
Cloning of NAMPT
Total RNA was purified from NYH/CHS, NYH/APO866,
HCT-116/APO866, HCT-116/TP201565 and PC-3/
TP201565 using Trizol reagent (Invitrogen, Carlsbad, CA,
USA). mRNA was converted to cDNA using TaqMan®
Reverse Transcription Kit (Applied Biosystem, Foster City,
CA, USA) which was used as template for full length PCR
of NAMPT by RED Extract-N-Amp™PCR ReadyMix™
(Sigma). PCR products of all cell lines were sequenced
twice and compared to NAMPT (GenBank accession #
U02020). NAMPT flanked by BamHI/XhoI restriction
sites was cloned into the TOPO TA cloning vector pCR
4-TOPO® (Invitrogen) and clones containing identified
mutations were selected. The mutated sequences were
enzymatically cut with ScaI and BsaI (New England Bio-
labs, Ipswich, MA, USA) and ligated into wild type
NAMPT in a pET28a(+) expression plasmid backbone
(a kind gift from Dr. Shin-Ichiro Imai from Washington
University School of Medicine, St. Louis USA) using T4
DNA ligase (New England Biolabs). Rosetta™2 (DE3) com-
petent cells (Novagen, Merck, Darmstadt, Germany) were
transformed with the resulting vectors. Sequencing was
used to confirm correct insertion of the mutations.
Transfection
NAMPTwt, NAMPTH191R, NAMPTD93del and
NAMPTQ388R/K342R with BamHI/XhoI restriction
sites were ligated into the mammalian expression vector
TRex pcDNA-4/TO/Myc.His (Invitrogen). 100 μls t e r i l e
water containing 20 μg/ml vector was mixed with 4 μl
FuGENE HD transfection agent (Roche, Basel, Switzer-
land). After 20 min the mix was added to 2 × 10
5 HEK-
293T cells plated in 2 ml DMEM medium (Invitrogen)
in 6-well plates 24 hours before transfection. After 24
hours, the cells were replated for experiments or for
establishment of stable cell lines (HEK/CTR and HEK/
NAMPTwt) in medium containing 300 ng/ml zeocin
(Invitrogen). Cell proliferation was examined using Cell-
TiterGlo (Promega, Madison, WI, USA) as described
previously [24] using 72 hours incubation.
Recombinant protein expression and determination of
enzymatic activity of NAMPT
The proteins were expressed as previously described
[12] using 5 hour induction at 37°C with 1.5 mM IPTG
(Sigma) and lysis was done in 20 mM Tris-HCl pH 8.0,
300 mM NaCl, 0.1% Triton X-100 and protease inhibi-
tor cocktail (Sigma) using sonication. His-Tagged
NAMPT proteins were purified using nickel-
nitrilotriacetic acid resin (Qiagen, Hilden, Germany) and
imidazole elution. Purity and yield was evaluated by SDS
gel electrophoresis and A280 measurements. Purified
His-Tagged NAMPT proteins (WT, H191R and D93del)
were incubated in reaction buffer (50 mM Tris-HCl [pH
8.5], 100 mM NaCl, 0.25 mM nicotinamide, 10 mM
MgSO4, 1.5% ethanol, 0.5 mM phosphoribosyl pyropho-
sphate, 2.0 mM ATP) for 55 min at 37°C. The reaction
was then coupled with NMNAT1 (cloned and expressed
similarly to NAMPT - as above) and alcohol dehydro-
genase (Sigma) 10 μg/ml each and incubated for further
5 minutes at 37°C. NMN production by NAMPT was
evaluated indirectly by measuring the fluorescence (340
nm excitation, 465 nm emission). Fluorescence created
by NADH was converted to NMN amounts using a
standard curve with known amounts of NMN. kcat
values were averaged from calculations of kcat for 500,
1000 and 2500 ng NAMPT enzyme. IC50 values for
APO866 were obtained using the same assay setup as
described above. For each enzymatic reaction 2000 ng
purified NAMPT was used. The concentrations of inhi-
bitor used to generate the inhibition curves were in the
range from 0 nM - 0.5 μM for the wild type NAMPT
and 0 nM - 100 μM for H191R.
Xenograft studies
All mouse experiments were performed in accordance
with national and EU legislation, and a permit to perform
the specific type of experiments was obtained from the
Experimental Animal Inspectorate, Danish Ministry of
Justice. 10
7 cells of the paternal or resistant cell line of
each of the four cell lines were injected s.c. in a mixture
of PBS/matrigel in the right and left flank of female
NMRI athymic mice (Taconic, Ry; Denmark), respec-
tively. The mice were observed daily and tumour volumes
were calculated from caliper measurements to estimate
the radius and using the formula for a sphere. Tumours
were allowed to reach a maximum volume of 1000 mm
3,
where after the mouse was sacrificed. Tissue samples of
the xenograft tumours were excised and placed in phos-
phate buffered formaldehyde (4%, pH 7) for at least a
week, and were then embedded in paraffin for sectioning
and H&E staining. In xenograft studies with either the
wild type or APO866-resistant variant of the HCT-116
tumour cell line mice were treated with a standard two
daily i.p. injections of 15-20 mg/kg APO866 in PBS with
1% hydroxypropyl-b-cyclodextrin/12% propylene glycol
on day 0-13, starting when tumour volumes were around
100 mm
3, as previously described [30].
Statistical analyses
Statistical analysis and the graphical presentation were per-
formed using the software GraphPad Prism® v. 4.0 (Graph-
Pad Software, Inc., San Diego, CA, USA). Tumour doubling
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exponential growth in Graph Pad Prism, and were com-
pared using Student’s t-test. The outcome of xenografts in
the treatment experiment was quantified as the number of
days until the tumour of each individual mouse reached a
size of 800 mm
3, expressed as survival days. The survival in
each treatment group was compared using log-rank analy-
sis. The level of significance was set to a p value of 0.05.
Measurement of NAMPT activity in lysates
Activity of NAMPT was examined in PC-3 and PC-3/
TP201565 as well as HEK293T cells and HEK/
NAMPTwt. NAMPT activity was measured by the con-
version of
14C-labelled nicotinamide to
14C-NMN using
a method previously described [31,32] using 50 μgt o t a l
protein from cell lysate. Briefly, lysate was incubated
with ATP, 5-phosphoribosyl-1-pyrophosphate and
14C-
nicotinamide in reaction buffer. The mix was transferred
to glass fibre filter and washed in acetone to remove
excess
14C-nicotinamide. Counts per minute (cpm)
determined by a liquid scintillation counter.
Computer modelling of NAMPT
The molecular modelling was based on the published X-
ray structure of NAMPT in complex with the inhibitor
APO866 (2.10 Å resolution, PDB id: 2GVJ) [14]. The
structure was imported into Maestro v. 9.0 release 111
and prepared for docking in the following way using the
protein preparation wizard (Schrodinger Suite 2009,
Schrodinger LLC, Oregon, USA). First, bond orders
were assigned and hydrogen atoms were added. The
four selenocysteines (Cys368 and Cys372 in both mono-
mers) which had been incorporated to facilitate X-ray
crystallographic analysis were mutated back to cysteine.
Water molecules further than 5Å away from the binding
site were removed, and finally the hydrogen bonding
network was optimized. The Glide docking module was
used for the docking of the ligands. Initially, the recep-
tor grid was generated (no vdW scaling of the receptor
atoms was applied). The enclosing box for the docking
of TP201565 and CHS-828 was based on the position of
APO866 in the X-ray crystal structure. The hydroxyl
groups in the receptor were allowed to rotate. For stu-
dies on the H191R mutation, APO866 was removed in
the 2GVJ X-ray structure which had already been pre-
pared for molecular modelling. The Prime module
allowed for introduction of the mutation, which was fol-
lowed by sampling of Arg191 dihedral angles to obtain
the most favorable orientation of the new side chain.
Precipitation assays with sepharose linked analogue of
TP201565
10 mg of the linkable analogue of TP201565 were
coupled to NHS activated sepharose (GE-Healthcare)
following the manufacturer’s instructions using
Na2CO3-containing reaction buffer and ethanolamine
for blocking. HCT-116 cells were lysed in MMENGM
buffer (25 mM MOPS pH[7,4], 2 mM EDTA, 2 mM
sodium orthovanadate, 1 mM NaN3, 10% glycerol and
0,1% NP-40) with (1:200) protease inhibitor cocktail
(Sigma) by sonication. Binding of NAMPT was con-
ducted by mixing 30 μg of cellular protein with 20 μl
coupled TP202648 beads and incubation for 60 min at
5°C with end over end rotation. After incubation, the
beads were spun down and the supernatant removed
followed by 3× washes with PBS (Invitrogen). Samples
were boiled for 5 min at 95°C and run on a SDS gel fol-
lowed by evaluation of the precipitated NAMPT protein
by western blotting. For competitive studies, lysates
were pre-incubated with APO866 (250 μM-2.5 nM) or
TP201565 (250 μM-2.5 nM) for 15 min at 5°C before
adding inhibitor linked beads and incubating for 60 min
at 5°C.
Results
Development of resistant cell lines and identification of
NAMPT mutations
We previously used the cell line NYH/CHS with resis-
tance towards CHS-828 to determine the mechanism of
action of CHS-828 as depletion of NAD, likely through
inhibition of NAMPT [24]. From sensitive cell lines we
developed a number of resistant cell lines to the
NAMPT inhibitor APO866: NYH/APO866 and HCT-
116/APO866, and to the CHS-828 analogue TP201565
(figure 1): HCT-116/TP201565 and PC-3/TP201565.
Furthermore, we attempted to induce resistance in sev-
eral other combinations of compounds and cell lines
including NYH and HepG2 (hepatoma) cells with
TP201565 and RPMI-8226 (myeloma) cells with
APO866. No high-grade, stable resistance developed
during 4 months of culture with drug (data not shown).
Further, we have previously suggested that the resistance
of NYH/CHS could be caused by a mutation in NAMPT
[24]. Thus, we sequenced the NAMPT gene in the resis-
tant cell lines and their parental lines. We found
acquired mutations in NYH/CHS, NYH/APO866, HCT-
116/APO866 and HCT-116/TP201565 but not in PC-3/
TP201565 (Table 1). We also found two mutations that
were present in both the HCT-116 parental cell line and
in the resistant derivates. One, 903G->A, was silent (not
shown) and previously identified as a SNP (rs11553095,
dbSNP build 130) whereas the other, 1025A->G,
resulted in a change in protein sequence of K342R.
Interestingly, the mutations H191R and D93del occurred
in both resistant cell lines of HCT-116 and NYH,
respectively. We correlated the positions of the muta-
tions in the protein sequence with their positions in a
NAMPT crystal structure published previously [14]. We
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the binding site of APO866 and nicotinamide or at the
dimer interface of NAMPT whereas K342R was located
distantly from either. All the mutations occurred in only
one allele. In HCT-116/APO866 and HCT-116/
TP201565, H191R and K342R were located on separate
alleles whereas in the latter cell line, Q388R and K342R
were located together on the same allele.
We studied the LD50 values of the sensitive and resis-
tant cell lines in a clonogenic survival assay. The paren-
tal cell lines were all sensitive with LD50 values of 1.5-11
nM for APO866 (Table 2). TP201565 was a more potent
compound in this clonogenic assay compared to
APO866 and CHS-828 (10-100 fold). Generally, the cell
lines displayed a high degree of cross-resistance (Table
3). NYH/CHS and NYH/APO866 displayed similar resis-
tance to the compounds (data not shown). Further, we
found that the resistance observed for each cell line was
retained after at least 15 weeks of culture without drug
(data not shown). Interestingly, we observed LD50
values of 5-10 μM for CHS-828 in HCT-116/APO866,
HCT-116/TP201565 and PC-3/TP201565 (Table 3) that
were lower than for APO866. Otherwise, this compound
shows similar or higher potency.
We also studied the protein expression of NAMPT in
the parental and resistant cell lines. We found a slight
up-regulation around 20% of NAMPT in HCT-116/
APO866 compared to HCT-116 (figure 2A). Further, we
observed higher levels of NAMPT in PC-3 cells com-
pared to other parental cell lines and a marked up-regu-
lation in PC-3/TP201565 compared to PC-3 (around
80%).
Over-expression of NAMPT variants induce APO866
resistance in sensitive HEK293T cells
To examine whether the acquired mutations are primar-
ily responsible for the resistance observed in the resis-
tant cell lines we over-expressed wild type NAMPT
(NAMPTwt) and NAMPT containing either the H191R,
D93del or Q388R/K342R mutations in HEK293T, a sen-
sitive cell line, and measured the resistance induced by
the NAMPT over-expression. We created a robust over-
expression of NAMPT (Figure 2B) and we found that
NAMPTwt induced an increase of resistance towards
APO866 by 20 fold (p < 0.005). A further relative
increase in resistance was induced by all mutant
NAMPTs with the order of induced resistance being
H191R>D93del>Q388R/K342R (Figure 2C). Over-
expression of NAMPT containing the Q388R/K342R,
H191R or D93del mutation yielded significantly greater
resistance compared with wild type NAMPT over-
expression (p = 0.007, p = 0.01 and p = 0.002, respec-
tively). The H191R and D93del mutations resulted in an
induced resistance in HEK293T cells towards APO866
similar to or above that of the corresponding resistant
cell line. No significant difference was observed between
untransfected HEK293T cells and HEK293T/CTR
(empty vector).
APO866 binding and enzyme activity is affected by
NAMPT mutations in vitro
To study further the H191R and D93del mutations we
purified recombinant NAMPTwt and NAMPT with
either mutation. Using a colorimetric, coupled assay we
Table 1 Acquired and occurring mutations identified in
NAMPT inhibitor resistant cell lines and parental line
HCT-116
Mutation Change in
protein
sequence
Position
HCT-116 1025A>G K342R b-sheet 11
HCT-116/
TP201565
1025A>G K342R b-sheet 11
1163A>G Q388R Dimer interface
572A>G H191R APO866 binding
site
HCT-116/APO866 1025A>G K342R b-sheet 11
572A>G H191R APO866
binding site
NYH/CHS 278-280del D93del Dimer
interface
NYH/
APO866
278-280del D93del Dimer
interface
The structural position of the mutations has been determined from a
published crystal structure of NAMPT [14]. All mutations are located in one
allele only. In HCT-116/TP201565 the mutations K342R and Q388R are located
on the same allele.
Table 2 Sensitivity of cell lines as measured in a
clonogenic survival assay
APO866 CHS-828 TP201565
NYH 1.5 ± 0.5 1.7 ± 1.2 0.02 ± 0.01
HCT-116 10.9 ± 6.1 12.2 ± 7.4 0.4 ± 0.3
PC-3 3.8 ± 3.1 8.8 ± 8.4 0.3 ± 0.3
LD50 values (measured in nM) of the parental cell lines NYH, HCT-116 and
PC-3 when treated with APO866, CHS-828 or TP201565. LD50 values are
represented with standard deviations.
Table 3 Fold increase of LD50 in resistant cell lines for
treatment with NAMPT inhibitors
APO866 CHS-828 TP201565
NYH/CHS 18.3 168 33.5
HCT-116/APO866 946 414 1,723
HCT-116/TP201565 2,364 774 10,103
PC-3/TP201565 8,324 624 19,675
The level of resistance of the resistant cell lines, NYH/CHS, HCT-116/APO866,
HCT-116/TP201565 and PC-3/TP201565 is shown for treatment APO866, CHS-
828 and TP201565. Values represent the ratio of LD50 of the resistant cell line:
LD50 of parental cell line as measured by clonogenic survival assay.
Olesen et al. BMC Cancer 2010, 10:677
http://www.biomedcentral.com/1471-2407/10/677
Page 5 of 13determined the kcat for NAMPTwt (measured per active
site), NAMPTH191R and NAMPTD93del. We found
that the activities of NAMPTH191R and NAMPTK342R
were reduced by ~50% by the mutations when com-
p a r e dt ow i l dt y p ew h e r e a sN A M P T D 9 3 d e ld i s p l a y e d
20% of the wild type activity (Figure 3A). We examined
t h ei n h i b i t o r ye f f e c to fA P O 8 6 6i nN A M P T w ta n d
NAMPTH191R. The IC50 value for inhibition of
NAMPTwt was 110 nM while we found an IC50 value
for NAMPTH191R of 8585 nM (Figure 3B). Further, we
found that APO866, CHS-828 and TP201565 did not
inhibit NMNAT (data not shown).
NAMPT mutations do not inhibit in vivo xenograft
growth and maintain resistance towards APO866
We studied whether the resistance induced in vitro would
have an effect on tumour viability in vivo.X e n o g r a f tm o d e l s
were performed for parental cell lines NYH, HCT-116 and
PC-3 as well as their resistant derivates, and tumour forma-
tion rates were not affected in the resistant cell lines com-
pared with parental cell lines. NYH tumours had a very fast
doubling time in xenografts (3.7 days) followed by HCT-
116 and PC-3 (8.9 and 10 days respectively). We observed
no significant change in tumour doubling times for the
resistant cell lines when compared to their wild type coun-
terparts (Figure 4A). However, HCT-116/APO866 had a
shorter tumour doubling time, 6.9 ± 1.8 days, compared
with HCT-116 (8.9 ± 1.6 days) (Figure 4A). We examined
tumour tissues histologically and found no obvious mor-
phological differences between untreated sensitive
xenografts and their resistant counterparts (Figure 4B).
Notably, although xenograft tumours from NAMPT inhibi-
tor-resistant derivatives of HCT-116 were found to contain
many necrotic areas, similar results were observed for par-
ental HCT-116 cells. Finally, we treated HCT-116 and
HCT-116/APO866 xenografts with 20 mg/kg APO866
daily for 14 days. We observed that APO866 increased the
lifespan significantly in HCT-116 xenografts, increasing the
median time for a tumour to reach the size of 800 mm
3
with 32% from 22 to 29 days, whereas treating the HCT-
116/APO866 xenografts with APO866 resulted in no effect
on the survival (Figure 4C), confirming in vivo resistance.
There were no differences in body weight between the
groups (data not shown).
PC-3/TP201565 and HEK293T/WT display high NAMPT
activity compared to PC-3 and HEK293T
Since PC-3/TP201565 cells contained no mutations in
NAMPT we examined whether the increased protein
expression could be responsible for the NAMPT inhibi-
tor resistance observed in the cell line. We studied the
total in vitro activity of NAMPT from lysates of PC-3
and PC-3/TP201565 untreated and in response to inhi-
bition with APO866. We found that the basal total
activity of NAMPT was four fold higher in the resistant
line compared to PC-3 in accordance with the higher
expression of NAMPT (Figure 5A+B). However, the
IC50 value for in vitro lysate treatment with APO866 was
not significantly increased. Similarly, we observed a strong
increase in total NAMPT activity when over-expressing
NAMPT in HEK293T cells compared with wild type
HEK293T cells (Figure 5C+D). Likewise, the IC50 was not
increased by over-expression although the absolute
NAMPT activity remained elevated at concentrations
above the IC50 compared with untreated wild type
HEK293T cells. Respective protein expression levels of
NAMPT for the cell lines are shown in Figure 2B for
Figure 2 NAMPT expression in tumor cell lines and transfected
HEK293T cells. A: Protein expression of NAMPT in parental and
resistant cell lines. 1-7: NYH, NYH/CHS, HCT-116, HCT-116/APO866,
HCT-116/TP201565, PC-3 and PC-3/TP201565. B: Comparison of
protein expression of NAMPT in 1 PC-3, 2 PC-3/TP201565, 3
HEK293T cells transfected with control vector and 4 HEK293T cells
transfected with an expression vector containing the NAMPT gene.
The expression is representative for transfections with wild type and
mutant NAMPT. GAPDH is used as loading control. C: IC50 values of
APO866 in HEK293T cells, untransfected and transfected with
control vector, wild type NAMPT and NAMPT containing H191R,
D93del or Q388R/K342R. Values are shown in nM ± SD.
Figure 3 In vitro NAMPT enzyme assays. A: kcat values for wild
type NAMPT (NAMPTwt) and NAMPT with K342R, H191R and
D93del mutations respectively. Statistical significance compared with
NAMPTwt: **: <0.0005, ***: <0.0001. B: IC50 values of APO866 for in
vitro inhibition of NAMPTwt and NAMPTH191R. The Y-axis is
logarithmic. Statistical significance compared with NAMPTwt: *:
<0,05. Error bars indicate SEM.
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1 and 2 pumps at the mRNA level and we found that PC-
3/TP201565 cells show no cross-resistance towards the
histone deacetylase inhibitor belinostat, the proteasome
inhibitor MG-132, the DNA methyltransferase inhibitor
5-azacytidine, the topoisomerase I inhibitor camptothecin,
the toposiomerase II inhibitors and ABC substrates doxor-
ubicin and mitoxantrone, retinoic acid, the IKK inhibitor
BMS-345541 or the protein kinase inhibitor staurosporine
(data not shown). The drugs were chosen to cover a broad
spectrum of mechanisms of action (including drugs sensi-
tive to MDR mechanisms) to give an indication of the
molecular basis of resistance in PC-3/TP201565 cells.
Docking studies confirm that APO866, CHS-828 and
TP201565 share a common binding site
To study the relationship between the active site of
NAMPT and APO866, CHS-828 and TP201565 as well
as the H191R mutation, we used computer modelling
based on a published x-ray structure of NAMPT [14].
The x-ray crystal structure contains several water mole-
cules located either within or close to the binding site,
hence we decided to carry out two separate docking runs;
one in which water molecules within 5Å of the APO866
binding site were included in the calculations, and
another without water molecules. Traditionally, docking
has been carried out using water-free enzyme active-site,
Figure 4 Subcutaneous xenograft experiments of parental and resistant cell lines. A: Tumour doubling times of NAMPT resistant cell lines
compared to tumour doubling times (TD) of parental cell lines (shown with SD). p-values are determined by t-tests. B: H&E stained sections of
xenograft tumours at 200× magnification. a NYH and b NYH/CHS xenografts contained cells of various sizes and showed many mitoses.
Tumours of c+e HCT-116, d HCT-116/APO866 and f HCT-116/TP201565 contain many fine connective tissue strands between tumour cells. Also,
necrotic foci and densely growing epithelial cells are observed. Morphology of g PC-3 and h PC-3/TP201565 varied between areas of rounded
cells and more spindle-shaped tumour cells. Many pyknotic (apoptotic) cell nuclei were also found. C: Cumulative survival of mice with HCT-116
and HCT-116/APO866 xenografts showing the time used by each mouse to grow its tumour to a size of 800 mm
3. The mice were treated with
15-20 mg/kg APO866 or vehicle twice daily for 14 days (0-13, double arrow), where day 0 indicates the day tumours had a size of approx. 100
mm
3. The result of log-rank analysis comparing APO866 treated mice with control mice in the respective xenografts (HCT-116: blue, HCT-116/
APO866: red) is shown on the graph.
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Page 7 of 13but recently with increased accuracy of crystal structures
and increased predictivity of computational chemistry
the importance of water molecules has been realized
[33]. If two ligands have very similar binding modes one
might therefore investigate whether the crystal waters
observed experimentally are also suitably positioned for
the ligand where no crystal structure is available.
When the water molecules were present in the binding
site, the highest-ranking docking conformation of APO866
was in good agreement with the reported X-ray structure
(RMS 0.2003Å for non-hydrogen atoms, XP glidescore
-8.92, Figure 6Aa). Surprisingly, also TP201565 was able to
dock into the solvated active site with the pyridine moiety
in the same π-stacking binding pocket between Tyr18’ and
Phe193. The double-headed TP201565 molecule could be
stabilized by displaying either the phenyl or the cyclo-hex-
ane in the opening of the narrow pore where APO866 has
a phenyl group (figure 6Ab+c, XP glidescores -8.29 and
-7.53, respectively). For CHS828 we did not obtain any
docked conformations with good XP glidescore (lower
than -6), indicating that the water-filled active site suitable
for APO866 is not compatible with this compound.
Then, we turned our attention to the docking experi-
ments carried out using the empty binding site without
water molecules. The best scoring conformation of
APO866 now had the phenyl group pointing towards the
other pocket (XP glidescore -8.18, shown as top view, Fig-
ure 7A), but a conformation similar to the crystal structure
was recovered as the fifth best conformation (XP glidescore
-6.98, data not shown). TP201565 was able to achieve a
good conformation (XP glidescore -7.78, top-view, Figure
7B). With the water molecules removed from the binding
site CHS-828 was also able to obtain good interactions (XP
glidescore -7.23, top-view, Figure 7C). All three compounds
Figure 5 Total in vitro activity of NAMPT in cell lysates. NAMPT activity as measured by conversion of C14-labelled nicotinamide to NMN by
50 μg of total protein from lysate untreated or with increasing concentrations of APO866. Absolute counts per minute (CPM) are presented. The
IC50 values have been averaged from at least 3 individual experiments. Cell lines measured are A PC-3, B PC-3/TP201565, C HEK293T and D
HEK293T/WT. Basal activity of PC-3/TP201565 is 4.0 fold higher than PC-3 and basal activity of HEK293T/WT is 7.4 fold higher than HEK293T. Error
bars indicate SEM; IC50 values are represented with standard deviations.
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Page 8 of 13had the pyridine substituent sandwiched between Tyr18’
and Phe193. The change from the alkene group in APO866
to the guanidinium group in TP201565 and CHS828 gave
rise to a H-bond between the NH-group proximal to the
pyridine and Asp219. While this caused these ligands to
move closer to Asp219 the long cyano-group still allowed
the formation of a H-bond to Ser275. The overall position
of CHS-828 in NAMPT without structural water present in
the binding site is shown in Figure 7D.
Further, we studied the effect of the H191R mutation
on binding APO866 in the active site. We found that
Arg-191 when modeled into NAMPT protruded into
the active site and sterically completely blocked binding
of APO866 (Figure 6B) as well as CHS-828 and
TP201565 (data not shown).
TP201565 is a competitive inhibitor of NAMPT in vitro
To confirm the notion gained from the computer modelling
results that CHS-828 and its analogues are competitive inhi-
bitors of NAMPT we used a modified analogue of TP201565
that contained a long carbon linker with a reactive amine
(Figure 8A). The analogue retained cytotoxic potency within
10 fold of unmodified TP201565 (data not shown). The ana-
logue was coupled covalently to sepharose beads and used
for protein precipitation from cellular lysate of HCT-116
cells. We found that linked TP201565 could bind and preci-
pitate NAMPT from lysate for analysis by western blot (Fig-
ure 8B). Pre-incubation of the lysate with APO866 blocked
the precipitation of NAMPT suggesting that the binding
sites of APO866 and TP201565 are overlapping. Since block-
ing NAMPT precipitation required relatively high concentra-
tions of APO866 we examined the blocking effect of
unmodified TP201565. We found that unmodifiedTP201565
was required in roughly the same concentrations for an effec-
tive abrogation of NAMPT precipitation (Figure 8B) indicat-
ing similar affinities for the binding site.
Discussion
Although CHS-828 has been established as an inhibitor
of NAD synthesis with a mechanism of action similar to
Figure 6 Computer modelling of NAMPT. A Binding of inhibitors in wild type NAMPT. a Binding of APO866 from x-ray structure and
computer modelling (XP glidescore -8.92) in the NAMPT active site superimposed. b The best docking of TP201565 in NAMPT with structural
water present in the active site XP (glidescores -8.29). c Alternative docking of TP201565 in the active site of NAMPT with switched positions of
the phenyl and cyclo-hexane groups (XP glidescore -7.53). d Docking of CHS-828 in NAMPT without structural water present (XP glidescore
-7.23). B Modelling of H191R. a The Arg191 of NAMPTH191R protrudes into the active site of NAMPT. b APO866 docking in the active site of
NAMPTH191R.
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Page 9 of 13APO866, it had not been definitively identified as an inhi-
bitor of NAMPT. Furthermore, previous attempts to
identify resistance mechanisms for CHS-828 have yielded
no definite results [24,34] and resistance to APO866 has
not been studied. In this study we introduce a novel
potent analogue of CHS-828, TP201565, that shows >10
fold increased activity in sensitive cancer cell lines com-
pared to APO866 and CHS-828. Using computer model-
ling, we find that CHS-828 and TP201565 most likely
function as inhibitors of NAMPT by binding to the same
site as APO866 and nicotinamide. This is further
supported by the fact that a sepharose linked TP201565
analogue can precipitate NAMPT from cellular lysate
and that this binding can be abrogated by co-incubation
with either APO866 or TP201565. We also show how
mutations in NAMPT can block the binding of APO866,
CHS-828 and TP201565. Together, these data conclu-
sively determine the pyridyl cyanoguanidines, CHS-828
and TP201565, as competitive inhibitors of NAMPT.
This is in agreement with very recently reported data,
which through the use of metabolic screens, in vitro
NAMPT assays and computer modelling reach a similar
conclusion for CHS-828 [35].
We developed four novel cell lines with acquired drug
resistance towards NAMPT inhibitors and including
NYH/CHS cells we observed mutations in all except
PC-3/TP201565. Interestingly, the H191R mutation was
detected in two different resistant cell lines derived from
HCT-116. Furthermore, the distinct deletion D93del was
located in both NYH/CHS and NYH/APO866. This sug-
gests that these mutations exist in a small subpopulation
of the parental cell line and that in these cases resis-
tance has been obtained from selection rather than de
novo mutations. The fact that we never obtained resis-
tance from treating NYH cells with TP201565 despite
prolonged growth with drug may be due to the fact that
cells containing the NAMPTD93del were not present in
the original flask used for inducing resistance to
TP201565. We found that the observed mutations in
NAMPT could induce resista n c es i m i l a rt oo ra b o v e
that seen in the original resistant cell line which strongly
suggests the mutations as the primary mechanistic cause
of resistance. Furthermore, we demonstrated that
whereas H191R abrogated NAMPT inhibitor binding in
computer modelling it only reduced the enzymatic
NAMPT activity in vitro by 50% - similar to what we
found for the K342R mutation. The change in kcat may
be due to altered substrate affinity resulting in an
Figure 7 Computer modelling of NAMPT without structural water present. A Top-view representation of APO866 binding. B Top-view
representation of TP201565. C Top-view representation of CHS-828.
Figure 8 Precipitation of NAMPT by sepharose linked
TP201565. A: Chemical structure of linkable TP201565 analogue B:
This figure shows western blots of NAMPT from 20 μg protein from
HCT-116 lysate as well as NAMPT precipitated from HCT-116 lysate
containing 20 μg total protein by TP201565 linked covalently to
sepharose beads. The binding of NAMPT to beads is performed
either with no inhibitor or in competition with a APO866 or b
TP201565 at concentrations between 250 μM and 2.5 nM (in 10-fold
steps).
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Page 10 of 13increased KM value. Also, we showed that the H191R
mutation strongly increased the IC50 value for APO866
inhibition in vitro. The relatively high IC50 value of
NAMPTwt obtained in vitro correlated with the pre-
vious results of others [35]. D93del on the other hand
reduced kcat in vitro. Although this may reduce overall
NAMPT activity compared to wild type NYH cells, it is
likely that enough NAD is produced to keep up with
the cellular demands and thus no growth disadvantage
is inferred. NYH/CHS cells have previously been shown
to retain the D93del mutation and full resistance after
30 passages without drug present in the media [24]
(unpublished results, Olesen, UH). Similarly we have
observed retained resistance for the remaining resistant
cell lines after culture for more that 15 weeks without
drug. We speculate that the induction of resistance by
D93del and Q388R may be due to interference with or
abrogation of dimerisation of NAMPT as both are
located in the dimer interface. The NAMPT monomer
may potentially retain lower enzymatic activity while not
binding the known NAMPT inhibitors. Alternatively,
the resistant cell lines may have adapted through
reduced NAD consumption or up-regulation of other
sources of NAD such as de novo synthesis.
Besides the data on the H191R mutation in figure 6B,
the observed difference in kinetics and inhibitory con-
stants between the different mutants cannot reliably be
predicted on the basis of the computer docking study
performed in this study. To achieve such correlations
molecular dynamics calculations of the entire enzyme
(including specific solvation) for tens of nanoseconds
would be necessary. However, this is far beyond what is
feasible with our current computational resources.
Notably, CHS-828 seems to show an upper level in
LD50 values around 5-10 μM which is significantly
lower than what is seen for APO866. We speculate that
this may be due to a secondary mechanism of cytotoxi-
city occurring at above 1 μM. This has also previously
been suggested [36,37]. Although this currently
unknown mechanism may be less important in cellular
and molecular assays, it may well be of interest clinically
for CHS-828, specifically since serum concentrations of
the drug have been reported to reach 11 μM in clinical
trials [26]. However, it is unlikely that it is related to the
previously proposed action of CHS-828 as an inhibitor
of the I-B kinase (IKK) complex [38]. CHS-828 showed
no inhibition of IKKa,I K K b or TBK1 enzymes in vitro
(unpublished results, Olesen, UH). APO866 displayed a
surprisingly specific induction of cell death in tumour
cells ranging five orders of magnitude from close to 1
nM to more than 30 μM in vitro and a similar specifi-
city was seen for TP201565. Finally, the specific nature
required of mutations in NAMPT to confer resistance
combined with the lack of resistance induced even at
prolonged drug treatment in a number of combinations
of cell lines and NAMPT inhibitors may indicate that
resistance is not induced frequently unless a suitable
mutation in NAMPT is already present in a population
of tumour cells. However, we also found that the resis-
tance is not easily reversible. Also, no significant
increase in tumour doubling times occurred in vivo for
the resistant cell lines. Rather, we find that HCT-116/
APO866 xenografts displayed reduced tumour doubling
times compared to HCT-116. As we did not observe a
similar trend for PC-3/TP201565 it seems unlikely to be
due to increased NAMPT levels. Rather, the induction
of resistance may have resulted in the development of
an unidentified growth advantage in HCT-116/APO866.
Further, the in vitro resistance also conferred insensitiv-
ity to APO866 treatment in xenograft models shown for
HCT-116/APO866.
The PC-3/TP201565 cell line is highly resistant
towards NAMPT inhibitors while displaying up-regula-
tion but no mutations of NAMPT. The up-regulation
could be due to increased gene copy number. We found
that the basal NAMPT activity in the resistant cell line
and also in transfected NAMPT over-expressing
HEK293T/WT was much higher than in wild type PC-3
and HEK293T cells. The fact that PC-3/TP201565 cells
displayed higher total activity than HEK293T/WT despite
the latter having higher expression of NAMPT agrees
with previous findings that endogenous NAMPT has
higher activity compared to recombinant NAMPT [39].
However, the IC50 was not significantly changed and
although the absolute NAMPT activity remained high
relative to wild type PC-3 and HEK293T at concentra-
tions of APO866 up to 1-10 μM, it would not seem to
fully explain the >10 μML D 50 value observed for
APO866 in PC-3/TP201565. Further, the resistance
appeared to be specific to NAMPT inhibitors as cross-
resistance to other chemotherapeutics was not observed
and it was not related over-expression of MDR1 and 2.
Also, CHS-828 has displayed only low to moderate sensi-
tivity to mechanisms of MDR based on over-expression
of Pgp170 and MRP, increased levels of gluthation and
tubulin-associated MDR [23,40]. Thus, we believe that
PC-3/TP201565 cells are likely to possess a further, yet
unknown, specific mechanism of resistance. Still, the
over-expression explains part of the resistance and, as
also seen for HEK293T/WT cells, high levels of NAMPT
may be sufficient to induce resistance which would be
significant in a clinical setting. This is similar to the situa-
tion with thymidylate synthase where high expression
levels predict resistance to 5-fluorouracil and a poor
treatment outcome [41,42].
The crystal structure of NAMPT in complex with
APO866 has previously led to suggestions on improving
the potency of APO866 based on its interaction with
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Page 11 of 13the NAMPT binding site [14,43]. So far, published
APO866 analogues have shown less activity in cellular
assays [44,45]. We found that the mutations in NAMPT
identified in the resistant cell lines show a tendency to
locate either in the binding site or dimer interface.
These mutations may directly or indirectly adjust the
s h a p eo ft h eb i n d i n gs i t es ot h a ti ti su n s u i t a b l ef o rt h e
relatively large NAMPT inhibitors while still accessible
for nicotinamide and NMN. Also, others have recently
published a single resistant cell line showing a point
mutation, G217R, which is close to the active site of
NAMPT and is responsible for high-grade resistance
towards CHS-828 [14,35]. We hope that the identifica-
tion of a new class of NAMPT inhibitors and the char-
acterization of resistance inducing mutations in
NAMPT may be useful in developing second-generation
NAMPT inhibitors with higher potency and potentially
less affected by acquired resistance.
Conclusions
We have identified the cyanoguanidines CHS-828 and
TP201565 as direct inhibitors of NAMPT. Further, we
found that NAMPT mutations located around the
enzyme active site or the dimer interface could be
expected to be the most frequent cause of acquired
resistance towards inhibitors of NAMPT. The location
of the mutations could be applied as guide for develop-
ment of next-generation NAMPT inhibitors with
reduced risk of development of resistance.
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